JP4065600B2 - Immunological assay and immunological assay kit - Google Patents
Immunological assay and immunological assay kit Download PDFInfo
- Publication number
- JP4065600B2 JP4065600B2 JP08856898A JP8856898A JP4065600B2 JP 4065600 B2 JP4065600 B2 JP 4065600B2 JP 08856898 A JP08856898 A JP 08856898A JP 8856898 A JP8856898 A JP 8856898A JP 4065600 B2 JP4065600 B2 JP 4065600B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sample
- human igm
- antigen
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Description
【０００１】
【発明の属する技術分野】
本発明は、免疫学的測定法に関し、より詳細には、試料中に存在する非特異因子により生じる非特異反応を抑制する免疫学的測定法に関する。
【０００２】
【従来の技術】
免疫学的測定法は抗原抗体反応を利用した測定法で、特異性が非常に高い測定法であることが知られている。免疫学的測定法としては、蛍光抗体法、間接血球凝集法、ラジオイムノアッセイ法、エンザイムイムノアッセイ法などが知られている。最近は、より高感度な化学発光免疫測定法、一般の生化学用分析装置で測定可能な免疫比濁法、ラテックス凝集光学的測定法などが開発され、特に医学分野においては頻繁に利用されている。
【０００３】
しかし、このような特異性の高い免疫学的測定法であっても、試料によっては測定しようとする抗原が存在しなくても陽性の測定値を示したり、真値とは異なった測定値を示したりする問題があった。すなわち、非特異反応と呼ばれる現象である。たとえば、測定しようとする抗原に対する抗体を固相化するような免疫学的測定法であるエンザイムイムノアッセイ法やラテックス凝集光学的測定法などでは、固相化抗体を認識してこれと反応する因子（非特異因子）が試料中に存在する場合があり、このような場合には試料中に測定しようとする抗原が存在しなくても陽性の測定値になったり、真値とは異なった測定値を示してしまうという問題があった。
【０００４】
【発明が解決しようとする課題】
従って、本発明の目的は、試料中に存在する非特異因子による影響を受けることなく、抗原を正確に測定することができる免疫学的測定法およびそれに用いることができるキットを提供することである。
【０００５】
【課題を解決するための手段】
本発明者らは、鋭意研究の結果、免疫学的測定法において、試料中に存在する非特異因子に対する抗体を免疫測定系に添加することにより、該非特異因子による非特異反応を抑制し、その結果として、抗原を正確に測定できることを見出し、本発明を完成させるに至った。すなわち、本発明は、試料中に存在する非特異因子に対する抗体を免疫測定系に添加することにより、該非特異因子による非特異反応を抑制することを特徴とする免疫学的測定法を提供する。試料中に存在する非特異因子としては、測定しようとする抗原に対する抗体を認識して、この抗体と反応するものであれば、特に限定されないが、ＩｇＭ型またはＩｇＧ型の自然抗体を挙げることができる。非特異因子に対する抗体としては、非特異因子を認識して、これと反応するものであれば、特に限定されないが、抗ヒトＩｇＭ抗体、抗ヒトＩｇＧ抗体を挙げることができる。免疫学的測定法としては、蛍光抗体法、間接血球凝集法、ラジオイムノアッセイ法、エンザイムイムノアッセイ法、化学発光免疫測定法、免疫比濁法、ラテックス凝集光学的測定法などが挙げられるが、ラテックス凝集光学的測定法が効果的である。
【０００６】
また、本発明は、試料中に存在しうる非特異因子に対する抗体を含む免疫学的測定用キットを提供する。試料中に存在しうる非特異因子およびそれに対する抗体としては、上記のものが挙げられる。本発明のキットは、さらに、試料のイオン強度や浸透圧などを緩衝する薬剤、たとえば、グリシン、Tris、Hepes などを含んでもよい。
本発明の方法およびキットは、臨床検査分野を始めとする医学分野、特に免疫学的手法に関係する分野に有用なものである。
【０００７】
【発明の実施の形態】
免疫学的測定にかける試料としては、種々の生体試料、例えば、被験者の血液、血清、血漿、尿、唾液などの体液、各種の細胞、組織を挙げることができる。
試料中に存在する非特異因子は、測定しようとする抗原に対する抗体を認識して、この抗体と反応するものである。たとえば、ラテックス凝集光学的測定法において、ラテックス粒子に結合させた測定しようとする抗原に対する抗体がウサギ免疫グロブリンＧ（ＩｇＧ）である場合には、ラテックス粒子表面上に結合したウサギＩｇＧを非特異因子が認識してこれと反応する。この非特異因子は、測定しようとする抗原で全く免疫されていない正常ウサギのＩｇＧも認識してこれと反応する。試料中に存在するこのような非特異因子は免疫などによって産生されたものでないため、自然抗体と呼ばれている。このような自然抗体は、免疫グロブリンＭ（ＩｇＭ）であったり、免疫グロブリンＧ（ＩｇＧ）であったりする。すなわち、非特異因子は、試料がヒト体液、たとえば血清や血漿の場合には、測定しようとする抗原に対する抗体を作製した動物のＩｇＧに対する抗動物ＩｇＧ抗体ヒトＩｇＭ型あるいは抗動物ＩｇＧ抗体ヒトＩｇＧ型である。この他にも、非特異因子としては、リウマチ因子、異好抗体などが知られている。
【０００８】
非特異因子に対する抗体は、非特異因子を認識して、これと反応するものであり、ＩｇＭ型の非特異因子の場合には、抗ヒトＩｇＭ抗体であり、ＩｇＧ型の非特異因子の場合には、抗ヒトＩｇＧ抗体であるが、これは一例である。非特異因子に対する抗体は、いずれの動物に免疫して作製されたものでも良いが、好ましくは測定しようとする抗原に対する抗体と同種の動物により作製されたものである。
【０００９】
本発明の方法において、非特異因子に対する抗体は、免疫測定系に添加される。具体的には、非特異因子に対する抗体の溶液を用意して、測定しようとする抗原に対する抗体を抗原と反応させる前に、あらかじめ試料に前記の溶液を添加して、非特異因子とそれに対する抗体を反応させることによって、非特異因子による非特異反応を抑制してもよいし、測定しようとする抗原に対する抗体の溶液中に非特異因子に対する抗体を含ませ、この溶液を試料に添加して、非特異因子とそれに対する抗体を反応させることによって、非特異因子による非特異反応を抑制してもよい。前者の方法において、非特異因子に対する抗体の溶液中の該抗体の量は、特に限定されないが、好ましくは抗体蛋白量0.1mg/mLから10mg/mLである。この溶液の組成は、特に限定されることはなく、抗体活性に安定なもので（すなわち、抗体の活性を失活させない）しかも測定しようとする抗原の測定系に影響を与えないものであればよい。また、後者の方法において、測定しようとする抗原に対する抗体の溶液中に含ませる非特異因子に対する抗体の量は、特に限定されないが、好ましくは抗体蛋白量0.1mg/mLから10mg/mLである。
【００１０】
本発明の免疫学的測定用キットは、試料中に存在しうる非特異因子に対する抗体をひとつの要素として含むが、その他にも、試料のイオン強度や浸透圧などを緩衝する薬剤、たとえば、グリシン、Tris、Hepes などの要素を含んでもよい。これらの要素は、バイアル、チューブなどのような容器に収納され、区画化された担持手段中にこれらの容器をひとまとめにして納められるとよい。
【００１１】
【実施例】
以下、本発明を実施例に基づきより具体的に説明する。もっとも、本発明は下記実施例に限定されるものではない。
参考例１
試料として、数名の急性心筋梗塞患者からの血清を用意し、これらの試料における非特異反応の有無を以下のようにして確認した。
【００１２】
血清試料を生理食塩液にて５段階希釈し、各々の試料10μLに第１試薬である0.17Mグリシン緩衝液、pH7.0を160μＬ添加したのち、Massonらの方法（Methods in enzymology, vol.74, 106-140）により抗ミオグロビン抗体ウサギＩｇＧを結合させたラテックス試薬である第２試薬を100μL添加して反応させ、各々の試料中のミオグロビン濃度を測定した。結果を図１に示す。図１に示されるように、希釈系列とミオグロビン濃度に比例関係があるものは非特異反応の無い試料であり、このような試料では、正確にミオグロビン濃度が定量できる。これに対して、希釈系列とミオグロビン濃度に比例関係が無いものは非特異反応のある試料であり、このような試料では、非特異因子が測定に影響を及ぼすために、正確なミオグロビン濃度の定量ができないことは明らかである。
【００１３】
実施例１
参考例１の非特異反応のある試料または非特異反応の無い試料を生理食塩液にて５段階希釈し、各々の試料10μLに、抗ヒトＩｇＭ抗体（ウサギＩｇＧ）1.0 mg/mLを含む第１試薬（0.17Mグリシン緩衝液、pH7.0）を160μＬ添加したのち、第２試薬（Massonらの方法により抗ミオグロビン抗体ウサギＩｇＧを結合させたラテックス試薬）を100μL添加して反応させ、各々の試料中のミオグロビン濃度を測定した。結果を図２に示す。図２に示されるように、非特異反応の無い試料では、第１試薬に抗ヒトＩｇＭ抗体（ウサギＩｇＧ）が含まれていても希釈系列とミオグロビン濃度には比例関係があり、正確にミオグロビン濃度を定量していることがわかる。また、非特異反応のある試料でも、第１試薬に抗ヒトＩｇＭ抗体（ウサギＩｇＧ）を含ませれば、参考例１の場合とは異なり希釈系列とミオグロビン濃度には比例関係があり、正確にミオグロビン濃度を定量していることがわかる。
【００１４】
参考例１および実施例１の結果から、次のことが言える。非特異因子による非特異反応が無い試料中のミオグロビン濃度は正確に定量できるが、参考例１では非特異反応のある試料では希釈系列とミオグロビン濃度には比例関係が無く、明らかに非特異因子による測定への影響があり、正確にミオグロビン濃度を定量できなかった。しかし、非特異因子に対する抗体、この実施例では抗ヒトＩｇＭ抗体（ウサギＩｇＧ）を第１試薬に含ませて試料に添加すれば、試料中の非特異因子の非特異反応を抑制することにより非特異反応のある試料でも希釈系列とミオグロビン濃度には比例関係が成立し、正確にミオグロビン濃度を定量できる。
【００１５】
実施例２
非特異因子の分画
参考例１の非特異反応のある試料200μLをSuperose 6にチャージし、ゲル濾過分画を行った。次に、各画分のミオグロビン濃度を参考例１の第１試薬（抗ＩｇＭ抗体を含まない）及び第２試薬のラテックス試薬を用いて参考例１と同様に測定した。ピークはミオグロビンの分子量的に分画される位置とそれより高分子側の分画位置とに確認された。この高分子側の分画を非特異因子分画とした。
【００１６】
非特異因子と抗ＩｇＭ抗体添加の効果
非特異反応のない試料として、健常人の血清を用意した。この非特異反応のない試料の少量をとり、これを試料Ａとした。また、同じ試料から別に少量とり、これに非特異因子分画を約１mg/mL（最終蛋白質量）添加して、試料Ｂとした。
【００１７】
試料ＡおよびＢの各10μLに、第１試薬（0.17Mグリシン緩衝液、pH7.0）を160μＬ、または抗ヒトＩｇＭ抗体（ウサギＩｇＧ）1.0 mg/mLを含む第１試薬を160μＬ添加したのち、第２試薬（Massonらの方法により抗ミオグロビン抗体ウサギＩｇＧを結合させたラテックス試薬）を100μL添加して反応させ、各々の試料中のミオグロビン濃度を測定した。その結果、表１に示すように試料Ａのミオグロビン濃度は抗ＩｇＭ抗体を含まない第１試薬を用いた場合と抗ＩｇＭ抗体を含んだ第１試薬を用いた場合とでほぼ同様の測定値であったが、試料Ｂのミオグロビン濃度は抗ＩｇＭ抗体を含まない第１試薬を用いた場合、試料Ａに比較して非常に高い値を示した。しかし、抗ＩｇＭ抗体を含んだ第１試薬を用いた場合の試料Ｂのミオグロビン濃度は試料Ａと同様の測定値であった。抗ＩｇＭ抗体を含まない第１試薬を用いた場合の試料Ｂのミオグロビン濃度が試料Ａに比較して非常に高い値を示したのは、非特異因子の添加によるものであり、抗ＩｇＭ抗体を含んだ第１試薬を用いた場合の試料Ｂのミオグロビン濃度が試料Ａと同様の測定値であったのは、第１試薬に抗ＩｇＭ抗体を添加することにより非特異因子の非特異反応を抑制したためである。このことは、抗ＩｇＭ抗体の添加により非特異因子による非特異反応を抑制し、その結果、ミオグロビンの正確な定量測定ができることを意味している。
【００１８】
【表１】
【発明の効果】
本発明の免疫学的測定法によれば、非特異因子を含む試料についても、該非特異因子により生じる非特異反応を抑制して、抗原を正確に測定することができる。
【図面の簡単な説明】
【図１】 参考例１で得られた非特異反応のある試料または非特異反応の無い試料の希釈系列とミオグロビン濃度の測定値との関係を示した図である。
【図２】 非特異因子に対する抗体を添加した場合の非特異反応のある試料または非特異反応の無い試料の希釈系列とミオグロビン濃度の測定値との関係を示した図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an immunological assay, and more particularly to an immunological assay that suppresses non-specific reactions caused by non-specific factors present in a sample.
[0002]
[Prior art]
The immunological measurement method is a measurement method using an antigen-antibody reaction, and is known to be a measurement method with very high specificity. As immunological measurement methods, fluorescent antibody methods, indirect hemagglutination methods, radioimmunoassay methods, enzyme immunoassay methods and the like are known. Recently, more sensitive chemiluminescence immunoassay methods, immunoturbidimetric methods that can be measured by general biochemical analyzers, latex agglutination optical measurement methods, etc. have been developed, and are frequently used especially in the medical field. Yes.
[0003]
However, even with such a highly specific immunoassay, depending on the sample, even if the antigen to be measured does not exist, it shows a positive measurement value or a measurement value different from the true value. There was a problem to show. That is, a phenomenon called non-specific reaction. For example, in the enzyme immunoassay method or the latex agglutination optical assay method, which is an immunological assay that immobilizes an antibody against the antigen to be measured, a factor that recognizes and reacts with the immobilized antibody ( (Non-specific factors) may be present in the sample. In such a case, even if the antigen to be measured is not present in the sample, the measured value will be positive or different from the true value. There was a problem of showing.
[0004]
[Problems to be solved by the invention]
Accordingly, an object of the present invention is to provide an immunological assay that can accurately measure an antigen without being affected by non-specific factors present in a sample, and a kit that can be used therefor. .
[0005]
[Means for Solving the Problems]
As a result of diligent research, the present inventors have added an antibody against a nonspecific factor present in a sample to an immunoassay system in an immunoassay, thereby suppressing a nonspecific reaction caused by the nonspecific factor, As a result, the inventors have found that the antigen can be accurately measured, and have completed the present invention. That is, the present invention provides an immunological assay characterized by suppressing a nonspecific reaction caused by a nonspecific factor by adding an antibody against the nonspecific factor present in a sample to the immunoassay system. The non-specific factor present in the sample is not particularly limited as long as it recognizes an antibody against the antigen to be measured and reacts with the antibody, and examples thereof include natural antibodies of IgM type or IgG type. it can. The antibody against the non-specific factor is not particularly limited as long as it recognizes and reacts with the non-specific factor, and examples thereof include anti-human IgM antibody and anti-human IgG antibody. Immunological measurement methods include fluorescent antibody method, indirect hemagglutination method, radioimmunoassay method, enzyme immunoassay method, chemiluminescence immunoassay method, immunoturbidimetric method, latex agglutination optical measurement method, etc. Optical measurement methods are effective.
[0006]
The present invention also provides an immunological assay kit comprising an antibody against a non-specific factor that may be present in a sample. Non-specific factors that can be present in the sample and antibodies against them include those described above. The kit of the present invention may further contain an agent that buffers the ionic strength, osmotic pressure, etc. of the sample, such as glycine, Tris, and Hepes.
The method and kit of the present invention are useful in the medical field including the clinical laboratory field, particularly in fields related to immunological techniques.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
Examples of samples subjected to immunological measurement include various biological samples, for example, body fluids such as blood, serum, plasma, urine, and saliva of subjects, various cells, and tissues.
The non-specific factor present in the sample recognizes an antibody against the antigen to be measured and reacts with this antibody. For example, in the latex agglutination optical measurement method, when the antibody to the antigen to be measured bound to latex particles is rabbit immunoglobulin G (IgG), rabbit IgG bound on the latex particle surface is used as a non-specific factor. Recognizes and reacts to this. This non-specific factor also recognizes and reacts with normal rabbit IgG that has not been immunized at all with the antigen to be measured. Such non-specific factors present in the sample are called natural antibodies because they are not produced by immunization or the like. Such natural antibodies may be immunoglobulin M (IgM) or immunoglobulin G (IgG). That is, when the sample is a human body fluid such as serum or plasma, the non-specific factor is an anti-animal IgG antibody human IgM type or anti-animal IgG antibody human IgG type against the IgG of the animal that produced the antibody against the antigen to be measured. It is. In addition, rheumatoid factors, heterophilic antibodies, and the like are known as non-specific factors.
[0008]
An antibody against a non-specific factor recognizes and reacts with a non-specific factor. In the case of an IgM type non-specific factor, it is an anti-human IgM antibody, and in the case of an IgG type non-specific factor. Is an anti-human IgG antibody, but this is an example. The antibody against the non-specific factor may be produced by immunizing any animal, but is preferably produced by the same kind of animal as the antibody against the antigen to be measured.
[0009]
In the method of the present invention, an antibody against a non-specific factor is added to an immunoassay system. Specifically, a solution of an antibody against a non-specific factor is prepared, and before the antibody against the antigen to be measured reacts with the antigen, the solution is added to the sample in advance, and the non-specific factor and the antibody against it are added. The nonspecific reaction by the nonspecific factor may be suppressed by reacting, or the antibody against the nonspecific factor is included in the solution of the antibody against the antigen to be measured, and this solution is added to the sample, By reacting a non-specific factor with an antibody thereto, a non-specific reaction caused by the non-specific factor may be suppressed. In the former method, the amount of the antibody in the solution of the antibody against the non-specific factor is not particularly limited, but the amount of antibody protein is preferably 0.1 mg / mL to 10 mg / mL. The composition of this solution is not particularly limited as long as it is stable to antibody activity (ie, does not deactivate antibody activity) and does not affect the measurement system of the antigen to be measured. Good. In the latter method, the amount of the antibody against the non-specific factor contained in the antibody solution against the antigen to be measured is not particularly limited, but the antibody protein amount is preferably 0.1 mg / mL to 10 mg / mL.
[0010]
The immunoassay kit of the present invention contains an antibody against a non-specific factor that may be present in a sample as one element, but in addition, an agent that buffers the ionic strength, osmotic pressure, etc. of the sample, such as glycine , Tris, Hepes, etc. These elements may be housed in containers such as vials, tubes, etc., and the containers may be packaged together in a compartmentalized carrier means.
[0011]
【Example】
Hereinafter, the present invention will be described more specifically based on examples. However, the present invention is not limited to the following examples.
Reference example 1
As samples, sera from several patients with acute myocardial infarction were prepared, and the presence or absence of non-specific reactions in these samples was confirmed as follows.
[0012]
Serum samples were diluted in five stages with physiological saline, and after adding 160 μL of 0.17 M glycine buffer solution, pH 7.0 as the first reagent to 10 μL of each sample, the method of Masson et al. (Methods in enzymology, vol. 74). , 106-140), 100 μL of a second reagent, which is a latex reagent to which anti-myoglobin antibody rabbit IgG was bound, was added and reacted, and the myoglobin concentration in each sample was measured. The results are shown in FIG. As shown in FIG. 1, the sample having no non-specific reaction has a proportional relationship between the dilution series and the myoglobin concentration. With such a sample, the myoglobin concentration can be accurately quantified. On the other hand, samples without a proportional relationship between the dilution series and myoglobin concentration are samples with non-specific reactions. In these samples, since non-specific factors affect the measurement, accurate quantification of myoglobin concentration is possible. Obviously you can't.
[0013]
Example 1
A sample with a non-specific reaction or a sample without a non-specific reaction of Reference Example 1 was diluted in 5 stages with physiological saline, and each sample (10 μL) contained 1.0 mg / mL anti-human IgM antibody (rabbit IgG). After adding 160 μL of a reagent (0.17 M glycine buffer, pH 7.0), 100 μL of the second reagent (latex reagent to which anti-myoglobin antibody rabbit IgG was bound by the method of Masson et al.) Was added, and reacted. The myoglobin concentration in the medium was measured. The results are shown in FIG. As shown in FIG. 2, in the sample having no non-specific reaction, even if the first reagent contains an anti-human IgM antibody (rabbit IgG), there is a proportional relationship between the dilution series and the myoglobin concentration, and the myoglobin concentration is accurately It turns out that it is quantifying. In addition, even in a sample having a non-specific reaction, if an anti-human IgM antibody (rabbit IgG) is included in the first reagent, unlike the case of Reference Example 1, there is a proportional relationship between the dilution series and the myoglobin concentration. It can be seen that the concentration is quantified.
[0014]
From the results of Reference Example 1 and Example 1 , the following can be said. The myoglobin concentration in the sample without non-specific reaction due to the non-specific factor can be accurately quantified. However, in Reference Example 1, the sample with non-specific reaction has no proportional relationship between the dilution series and myoglobin concentration, and clearly depends on the non-specific factor. There was an influence on the measurement, and the myoglobin concentration could not be accurately quantified. However, if an antibody against a non-specific factor, in this example, an anti-human IgM antibody (rabbit IgG), is added to the sample and added to the sample, the non-specific reaction of the non-specific factor in the sample is suppressed, thereby suppressing non-specific factors. Even in a sample with a specific reaction, a proportional relationship is established between the dilution series and the myoglobin concentration, and the myoglobin concentration can be accurately determined.
[0015]
Example 2
Fractionation of non-specific factors
200 μL of the sample with non-specific reaction of Reference Example 1 was charged into Superose 6 and subjected to gel filtration fractionation. It was then measured in the same manner as in Reference Example 1 using a latex reagent of each fraction of myoglobin concentration first reagent of Reference Example 1 (without anti-IgM antibody) and a second reagent. The peak was confirmed at the position where the molecular weight of myoglobin was fractionated and the position where the polymer was fractionated. This fraction on the polymer side was defined as a non-specific factor fraction.
[0016]
Effect of addition of non-specific factor and anti-IgM antibody A serum of a healthy person was prepared as a sample having no non-specific reaction. A small amount of the sample having no nonspecific reaction was taken as Sample A. In addition, a small amount was taken from the same sample, and about 1 mg / mL (final protein amount) of the non-specific factor fraction was added thereto to prepare Sample B.
[0017]
After adding 160 μL of the first reagent (0.17 M glycine buffer, pH 7.0) or 160 μL of the first reagent containing 1.0 mg / mL of anti-human IgM antibody (rabbit IgG) to 10 μL of each of samples A and B, 100 μL of the second reagent (latex reagent to which anti-myoglobin antibody rabbit IgG was bound by the method of Masson et al.) Was added and reacted, and the myoglobin concentration in each sample was measured. As a result, as shown in Table 1, the myoglobin concentration of sample A was almost the same measured value when the first reagent not containing anti-IgM antibody was used and when the first reagent containing anti-IgM antibody was used. However, the myoglobin concentration of sample B was much higher than that of sample A when the first reagent containing no anti-IgM antibody was used. However, the myoglobin concentration of Sample B in the case of using the first reagent containing anti-IgM antibody was the same measured value as Sample A. The reason why the myoglobin concentration of the sample B in the case of using the first reagent not containing the anti-IgM antibody was very high compared to the sample A was due to the addition of a non-specific factor. The myoglobin concentration of sample B when using the first reagent included was the same as that of sample A. The addition of anti-IgM antibody to the first reagent suppressed the nonspecific reaction of nonspecific factors. This is because. This means that the addition of an anti-IgM antibody suppresses a nonspecific reaction caused by a nonspecific factor, and as a result, accurate quantitative measurement of myoglobin can be performed.
[0018]
[Table 1]
【The invention's effect】
According to the immunological measurement method of the present invention, it is possible to accurately measure an antigen even in a sample containing a non-specific factor by suppressing a non-specific reaction caused by the non-specific factor.
[Brief description of the drawings]
FIG. 1 is a view showing the relationship between a dilution series of a sample with non-specific reaction or a sample without non-specific reaction obtained in Reference Example 1 and a measured value of myoglobin concentration.
FIG. 2 is a diagram showing the relationship between a dilution series of a sample with a non-specific reaction or a sample without a non-specific reaction when an antibody against a non-specific factor is added and a measured value of myoglobin concentration.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08856898A JP4065600B2 (en) | 1998-04-01 | 1998-04-01 | Immunological assay and immunological assay kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08856898A JP4065600B2 (en) | 1998-04-01 | 1998-04-01 | Immunological assay and immunological assay kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11287801A JPH11287801A (en) | 1999-10-19 |
| JP4065600B2 true JP4065600B2 (en) | 2008-03-26 |
Family
ID=13946477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP08856898A Expired - Lifetime JP4065600B2 (en) | 1998-04-01 | 1998-04-01 | Immunological assay and immunological assay kit |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4065600B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010026758A1 (en) | 2008-09-05 | 2010-03-11 | 積水メディカル株式会社 | Monoclonal antibody, and immunoassay using same |
| WO2013146977A1 (en) | 2012-03-30 | 2013-10-03 | デンカ生研株式会社 | Immunological analysis method and reagent |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2609280T3 (en) | 2007-08-23 | 2017-04-19 | Lsi Medience Corporation | Non-specific reaction inhibitor |
| JP4514233B2 (en) * | 2007-11-30 | 2010-07-28 | 田中貴金属工業株式会社 | Immunochromatography test kit |
| EP2902782B1 (en) * | 2012-09-28 | 2019-02-27 | Sekisui Medical Co., Ltd. | Immunological detection process and reagent for immunological detection process |
| JP6084759B1 (en) * | 2015-08-17 | 2017-02-22 | 積水メディカル株式会社 | Immunological detection method and test strip used therefor |
| JP6943789B2 (en) | 2018-02-21 | 2021-10-06 | 田中貴金属工業株式会社 | Monoclonal antibodies and non-specific reaction inhibitors |
| US11959917B2 (en) | 2018-09-18 | 2024-04-16 | Siemens Healthcare Diagnostics Inc. | Methods and reagents for Zika virus immunoassays |
| WO2024048583A1 (en) * | 2022-08-29 | 2024-03-07 | 積水メディカル株式会社 | Immunoassay method, non-specific reaction suppression method, immunoassay reagent, immunoassay reagent kit, composition, non-specific reaction suppressing agent, and use |
-
1998
- 1998-04-01 JP JP08856898A patent/JP4065600B2/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010026758A1 (en) | 2008-09-05 | 2010-03-11 | 積水メディカル株式会社 | Monoclonal antibody, and immunoassay using same |
| WO2013146977A1 (en) | 2012-03-30 | 2013-10-03 | デンカ生研株式会社 | Immunological analysis method and reagent |
| KR20140145121A (en) | 2012-03-30 | 2014-12-22 | 덴카 세이켄 가부시키가이샤 | Immunological analysis method and reagent |
| US9939436B2 (en) | 2012-03-30 | 2018-04-10 | Denka Seiken Co., Ltd. | Immunological analysis method and reagent |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11287801A (en) | 1999-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5057402B2 (en) | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies | |
| US4332783A (en) | Process for immunologic determination tests | |
| US4294817A (en) | Method of fluoro immunoassay | |
| US4894347A (en) | Erythrocyte agglutination assay | |
| WO2002039114A2 (en) | Improved assay and reagents or immunological determination of analyte concentration | |
| JP2636331B2 (en) | One-step assay for antigen-specific antibodies and suitable reagents | |
| MX2011002337A (en) | Monoclonal antibody, and immunoassay using same. | |
| JPH07508102A (en) | assay | |
| US4239743A (en) | Carrier-bound immunoglobulin fission product and its use in immunologic analyses | |
| JP4065600B2 (en) | Immunological assay and immunological assay kit | |
| US20040023309A1 (en) | Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample | |
| JP4918556B2 (en) | An immunoassay (recovery immunoassay) for simultaneously measuring an analyte (antigen) in a sample and a therapeutic antibody targeting the analyte immunochemically | |
| JP2009517667A5 (en) | ||
| KR920005964B1 (en) | Process for the determination of antibodies which are class-specific for an antigen and a reagent for carrying out the process | |
| EP0353306B1 (en) | Element for assaying rheumatoid factor and method of assaying | |
| EP0106615A2 (en) | Assay for the free portion of substances in biological fluids | |
| JP2004325414A (en) | Method and kit for measuring immunity | |
| JP4507439B2 (en) | Latex immunoturbidimetric assay and kit used therefor | |
| EP0333801B1 (en) | Test strip for diagnosis by multi-immunoassay system | |
| JP3298812B2 (en) | Method for measuring urinary trypsin inhibitor | |
| EP0485377A1 (en) | Solid phase immuno-assay with labelled conjugate | |
| JPH10319017A (en) | Measuring method for substance utilizing fluorescent energy transfer and reagent therefor | |
| JPH08292192A (en) | Immunoassary | |
| EP1596198A1 (en) | Method of measuring oxidized ldl-crp complex and measrurement kit | |
| JPH08193999A (en) | Immune measuring method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040113 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20040317 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20040409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040420 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040824 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050524 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050722 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050722 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050826 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051005 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20051202 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070730 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080107 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120111 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130111 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130111 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140111 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |